Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

and even liver failure. Previously, MASH was known as nonalcoholic steatohepatitis (NASH) since people who drink very little or no alcohol often develop the condition. While most people with MASH ...

But one risk you may not be as familiar with is metabolic dysfunction–associated steatohepatitis (MASH). MASH is a type of liver inflammation and damage caused by a buildup of fat in the liver.

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

MASH, which was previously known as non–alcohol related steatohepatitis (NASH), is often asymptomatic or leads to nonspecific symptoms, making progression to more severe stages of liver disease ...

Though it causes no permanent damage, NAFLD can progress to nonalcoholic steatohepatitis (NASH), which can result in ...

THURSDAY, Jan. 30, 2025 (HealthDay News) -- Weight-loss surgery can protect the liver health of patients ... called metabolic dysfunction-associated steatohepatitis (MASH), researchers said.

Patients who were obese had a 72% lower risk of major complications from liver disease They also ... also called metabolic dysfunction-associated steatohepatitis (MASH), researchers said.